中國心連心化肥(01866.HK)前三季度純利升2%至4.2億元
格隆匯11月20日丨中國心連心化肥(01866.HK)發佈公告,截至2020年9月30日止9個月,公司收入75.29億元人民幣,同比增長7%;期間純利4.2億元,同比增長2%。
期間成品尿素的銷量約為1,491,000噸,同比下降約為2%,銷售收入約為人民幣23.43億元,同比減少12%。這主要是受到市場大環境影響,造成本集團成品尿素的平均售價同比下降約11%。
車用尿素溶液的銷量約為296,000噸,同比增長約340%,銷售收入約為人民幣4.14億元,同比增加376%。主要得益於國家對環保治理工作的日益重視,在今年5月份出台了《關於調整輕型汽車國六排放標準實施有關要求的公告》,提高了機動車尾氣排放標準,要求嚴格控制限值。本集團藉助國家政策的有利條件,擴大營銷網絡、拓展分銷渠道,從而使車用尿素溶液的銷量顯着增長。車用尿素溶液的市場前景將繼續看好,具有很大的發展潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.